Quizartinib vs XY0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline
Quizartinib
Marketed by Daiichi Sankyo and partners
NCT02668653 · Phase 3 · completed
The trial randomized 539 participants to quizartinib plus chemotherapy or placebo plus chemotherapy, with participants, investigators, and outcome assessors masked. Its hard primary endpoint, overall survival, was met in favor of quizartinib, with a statistically significant hazard ratio of 0.776 (p=0.0324).
Next expected readout: May 2027 · NCT03793478 (registry estimate)
Reported efficacy
Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) (met)
Result source: NCT02668653
XY0206
Developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT05876832 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Quizartinib | XY0206 |
|---|---|---|
| OS, median | 31.9 vs 15.1+16.8 vs placeboNCT026686538 other results
| —Trial running · NCT05876832 |
| Complete remission | 2.6%bNCT015656681 other result
| —Trial running · NCT05876832 |
| Event-free survival, median | 0.0 vs 0.7−0.7 vs placeboNCT026686535 other results
| —Trial running · NCT05876832 |
| Duration of response, median | 3.6bNCT009892613 other results
| —Trial running · NCT05876832 |
OS, median
- Quizartinib
- 31.9 vs 15.1+16.8 vs placeboNCT02668653
8 other results
- 6.2 vs 4.7 NCT02039726
- 5.5 NCT00989261
- 6.3 NCT01565668
- 4.8 NCT01565668
- 5.9 NCT00989261
- 7.9 NCT02984995
- 4.4 NCT00989261
- 5.8 NCT00989261
- XY0206
- —Trial running · NCT05876832
Complete remission
- Quizartinib
- 2.6%bNCT01565668
1 other result
- 5.3% NCT01565668
- XY0206
- —Trial running · NCT05876832
Event-free survival, median
- Quizartinib
- 0.0 vs 0.7−0.7 vs placeboNCT02668653
5 other results
- 1.4 vs 0.8 NCT02039726
- 3.2 NCT01565668
- 2.8 NCT01565668
- 2.9 NCT02984995
- 0.0 NCT02984995
- XY0206
- —Trial running · NCT05876832
Duration of response, median
- Quizartinib
- 3.6bNCT00989261
3 other results
- 3.3 NCT00989261
- 5.2 NCT00989261
- 1.9 NCT00989261
- XY0206
- —Trial running · NCT05876832
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
XY0206: no structured comparison results are available for Acute Myeloid Leukemia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Quizartinib: 4 of 4 rows · XY0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Quizartinib |
|---|---|
| Dropout rate | 79.1%a NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results18.4% NCT02039726 · Phase 3 · registry result, not featured evidence 73.5%30 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence —20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 100%20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence n/a: no completion milestone60 mg NCT01565668 · Phase 2 · registry result, not featured evidence n/a: no completion milestone30 mg NCT01565668 · Phase 2 · registry result, not featured evidence 9.6%Cohort 1; ≥60 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 12.5%Cohort 2; ≥18 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 0%Phase 1 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 2 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 2 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 66.7%40 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence 50%20 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence 100%60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 16.7%60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 0%40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 20%40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 0%25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 1 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —450 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —135 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —90 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —60 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —40 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —27 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —18 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —12 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 21.6%a NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results— NCT02039726 · Phase 3 · registry result, not featured evidence 2.9%30 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence —20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 0%20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 2.6%60 mg NCT01565668 · Phase 2 · registry result, not featured evidence 15.8%30 mg NCT01565668 · Phase 2 · registry result, not featured evidence —Cohort 1; ≥60 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence —Cohort 2; ≥18 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence —Phase 1 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —40 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence —20 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 1 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —450 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —135 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —90 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —60 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —40 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —27 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —18 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —12 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 55.1%a NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results69.7% NCT02039726 · Phase 3 · registry result, not featured evidence 41.2%30 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 100%20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence —20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 63.9%60 mg NCT01565668 · Phase 2 · registry result, not featured evidence 65.8%30 mg NCT01565668 · Phase 2 · registry result, not featured evidence 85.4%Cohort 1; ≥60 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 76.7%Cohort 2; ≥18 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 20%Phase 1 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 40%Phase 2 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 65.6%Phase 2 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 66.7%40 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence 0%20 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 50%ALL Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence 0%ALL Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence 66.7%AML Dose Level 1 NCT01411267 · Phase 1 · registry result, not featured evidence 60%AML Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence 40%AML Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence 83.3%450 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 100%300 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence 75%300 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 52.9%200 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence 50%200 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 80%135 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 66.7%90 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 80%60 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 60%40 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 16.7%27 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 50%18 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 33.3%12 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a pyrexia 42.6% (placebo 39.6%) febrile neutropenia 37% (placebo 36.2%) diarrhoea 36.6% (placebo 35.1%) NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 30 more results30 mg/day platelet count decreased 38.2% electrocardiogram qt prolonged 35.3% febrile neutropenia 29.4% NCT02984995 · Phase 2 · registry result, not featured evidence 20 mg/day nausea 66.7% transfusion reaction 66.7% anemia 33.3% NCT02984995 · Phase 2 · registry result, not featured evidence 60 mg nausea 47.2% pyrexia 38.9% diarrhea 36.1% NCT01565668 · Phase 2 · registry result, not featured evidence 30 mg anemia 47.4% fatigue 34.2% febrile neutropenia 31.6% NCT01565668 · Phase 2 · registry result, not featured evidence nausea 54.1% diarrhea 41.4% fatigue 39.5% NCT00989261 · Phase 2 · registry result, not featured evidence nausea 50.6% vomiting 39.8% diarrhea 38.1% NCT00989261 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 80% blood bilirubin increased 80% hypocalcemia 80% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination alanine aminotransferase increased 100% allergic rhinitis 100% anemia 100% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination hypomagnesemia 65.7% creatinine decreased 62.9% hypokalemia 62.9% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination pain 50% nausea 43.8% diarrhea 40.6% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 40 mg/day electrocardiogram qt prolonged 100% febrile neutropenia 100% alopecia 66.7% NCT02834390 · Phase 1 · registry result, not featured evidence 20 mg/day febrile neutropenia 100% abdominal pain upper 75% alopecia 75% NCT02834390 · Phase 1 · registry result, not featured evidence platelet count decreased 100% anemia 50% ara-c skin rash 50% NCT01411267 · Phase 1 · registry result, not featured evidence hypokalemia 100% anemia 50% arthralgia 50% NCT01411267 · Phase 1 · registry result, not featured evidence anemia 100% white blood cell decreased 100% alanine aminotransferase increased 66.7% NCT01411267 · Phase 1 · registry result, not featured evidence white blood cell decreased 100% anemia 80% febrile neutropenia 60% NCT01411267 · Phase 1 · registry result, not featured evidence hypokalemia 90% hypomagnesemia 80% platelet count decreased 70% NCT01411267 · Phase 1 · registry result, not featured evidence 450 mg ID asthenia 66.7% diarrhoea 66.7% disease progression 66.7% NCT00462761 · Phase 1 · registry result, not featured evidence 300 mg CD ecg qt prolonged 50% anaemia 37.5% cough 37.5% NCT00462761 · Phase 1 · registry result, not featured evidence 300 mg ID anaemia 50% dyspnoea 50% fatigue 50% NCT00462761 · Phase 1 · registry result, not featured evidence 200 mg CD pyrexia 41.2% vomiting 41.2% epistaxis 35.3% NCT00462761 · Phase 1 · registry result, not featured evidence 200 mg ID nausea 83.3% chills 50% diarrhoea 50% NCT00462761 · Phase 1 · registry result, not featured evidence 135 mg ID fatigue 60% febrile neutropenia 60% nausea 40% NCT00462761 · Phase 1 · registry result, not featured evidence 90 mg ID febrile neutropenia 100% headache 66.7% nausea 66.7% NCT00462761 · Phase 1 · registry result, not featured evidence 60 mg ID disease progression 80% anaemia 60% nausea 60% NCT00462761 · Phase 1 · registry result, not featured evidence 40 mg ID pyrexia 60% anaemia 40% cough 40% NCT00462761 · Phase 1 · registry result, not featured evidence 27 mg ID nausea 50% anaemia 33.3% fatigue 33.3% NCT00462761 · Phase 1 · registry result, not featured evidence 18 mg ID diarrhoea 37.5% dizziness 37.5% hypokalaemia 37.5% NCT00462761 · Phase 1 · registry result, not featured evidence 12 mg ID abdominal pain 66.7% cough 66.7% asthenia 33.3% NCT00462761 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 37 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Quizartinib
show 1 more result
show 1 more result
show 1 more result
show 5 more results
show 5 more results
show 7 more results
show 3 more results
show 3 more results
+ 20 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Quizartinib's landscape · XY0206's landscape